Ipsen has agreed to acquire Memo Therapeutics AG, a late-stage biotech based in Schlieren near Zurich, in a deal centered on potravitug, a Phase II antibody for BK polyomavirus in kidney transplant recipients.
Under the definitive share purchase agreement, Memo shareholders will receive €200 million at closing on a cash-free, debt-free basis, with additional payments tied to development, regulatory and sales milestones that could bring the total value to more than €700 million. The transaction is expected to close in Q3 2026, subject to customary conditions.
The acquisition gives Ipsen a clinical-stage rare disease asset targeting a serious post-transplant complication for which there are currently no approved targeted therapies. Before closing, Memo’s non-potravitug assets and related employees will be transferred to a newly formed company, Memorises Bio, which will remain with existing shareholders.
Under the definitive share purchase agreement, Memo shareholders will receive €200 million at closing on a cash-free, debt-free basis, with additional payments tied to development, regulatory and sales milestones that could bring the total value to more than €700 million. The transaction is expected to close in Q3 2026, subject to customary conditions.
The acquisition gives Ipsen a clinical-stage rare disease asset targeting a serious post-transplant complication for which there are currently no approved targeted therapies. Before closing, Memo’s non-potravitug assets and related employees will be transferred to a newly formed company, Memorises Bio, which will remain with existing shareholders.